You will not find a schedule here, and the FDA label publishes none either [1]. It says only that treatment should be stopped gradually, to avoid signs and symptoms of withdrawal [1]. No amounts, no step sizes, no day counts appear on this page, and that is deliberate.
There is no universal plan because there is no universal patient. MedlinePlus puts the same point to patients directly. Your doctor will tell you when and how to stop taking buprenorphine, or buprenorphine and naloxone [2].
What this page can do is tell you how that decision gets made, what supervision adds, and what goes wrong when people build their own plan from something they read. Our overview of buprenorphine in treatment covers the medicine itself.
Why There Is No Standard Suboxone Taper
Because the starting point is different for every person on it. Buprenorphine is a partial agonist at the mu-opioid receptor, and chronic use produces physical dependence of the opioid type [1].
That dependence shows itself as moderate withdrawal signs and symptoms after abrupt discontinuation or a rapid reduction [1]. How much of it there is, and how quickly it eases, depends on how long someone has been treated, what they were using before, and what else is going on in their body.
The medicine is also long-acting by design. Taken under the tongue or against the cheek, buprenorphine has a mean elimination half-life ranging from 24 to 42 hours [1]. Naloxone, the second component, clears far faster, with a mean elimination half-life of 2 to 12 hours [1]. A long half-life changes how a reduction is felt, and when.
This is why a plan copied from a forum post fails. It was built for a body that is not yours, from a starting point that is not yours, by someone who could not see the rest of your history.
What a Prescriber Weighs Before Anything Changes
The first question is usually not how, but whether, and when.
Buprenorphine is one of three medicines the FDA has approved for opioid use disorder, along with methadone and naltrexone [3]. It is a treatment rather than a stage to be got through, and staying on it is a legitimate long-term outcome. The label itself notes the potential to relapse to illicit drug use after stopping opioid agonist or partial agonist treatment [1]. That risk is part of the decision, not an afterthought.
Beyond that, a prescriber is looking at your liver. The label reports higher plasma levels and longer half-lives for both buprenorphine and naloxone in people with moderate or severe liver impairment, with the larger effect on naloxone [1]. In mild impairment, and in people with hepatitis C but no sign of impairment, the label reports no clinically significant change [1].
They are also looking at your other medicines. Drugs that inhibit the CYP3A4 enzyme can raise buprenorphine levels; inducers can lower them, which can bring on a withdrawal syndrome in someone whose body has adapted [1]. A taper planned without that information is a taper planned in the dark.
Finally, they are looking at what else is being used, and at whether life outside the clinic is steady enough for this to be the right month.
What Supervision Actually Adds
Less drama than people expect, and more measurement. The label’s instruction is to monitor patients for withdrawal and treat appropriately if treatment is interrupted or stopped [1].
In practice that means the plan is written down, then checked against how the person is actually doing, and changed when the two disagree.
Withdrawal severity is scored rather than guessed. The World Health Organization’s guidance for withdrawal management describes using a short opioid withdrawal scale to track symptoms and to select the right level of response [4]. A score is not a verdict. It is a way of noticing a problem before the person in it has to argue for help.
Symptomatic treatment sits alongside that, for the things withdrawal actually does: nausea, cramps, sleeplessness, anxiety [4]. And the setting can change if the plan is not holding. That is the part a solo attempt cannot offer.
Our explainer on medication assisted treatment sets out how medicine and therapy work together, and medical detox covers the most supervised end of the ladder.
Talking to a prescriber about coming off Suboxone in Washington
The Recovery Village Ridgefield is in Ridgefield, Washington, and its own page publishes medical detox, inpatient treatment, partial hospitalization programming, intensive outpatient programming, dual diagnosis treatment and medically-assisted treatment. We also run a detox center in Vancouver, Washington, so the nearest option depends on which level of care the assessment recommends.
See treatment options in Washington
Verify your insurance
The Recovery Village Ridgefield is part of our family of treatment centers. See the Recovery Village Ridgefield campus.
Why Stopping on Your Own Is the Risky Version
Two risks, and they are different in kind.
The first is the one people expect. Stopping buprenorphine, or buprenorphine and naloxone, too quickly can cause withdrawal symptoms [2]. MedlinePlus lists what that can feel like: hot or cold flushes, restlessness, teary eyes, runny nose, sweating, chills, muscle pain, vomiting or diarrhea [2]. Unpleasant, and for most people not dangerous on its own.
The second risk is the one that kills people, and it arrives after the hard part is over. Withdrawal reduces a person’s tolerance, so someone who has just come through it can overdose on a much smaller amount than they used to take [5]. Anyone who comes off a medicine and then returns to opioid use is at their most vulnerable in exactly the window when they feel they have got past the worst.
If someone is having a seizure, is unresponsive or has trouble breathing, call 911. For a mental-health crisis call or text 988.
There is a third thing worth naming, which is not medical. A self-directed stop tends to happen at the worst possible moment, because it is usually triggered by something else going wrong. A prescriber-led plan exists partly to put a pause between the impulse and the change.
So the instruction from MedlinePlus is short and this page repeats it as written. Do not stop taking buprenorphine, or buprenorphine and naloxone, without talking to your doctor [2].
What Changes the Plan: Liver Function, Other Medicines, Other Substances
A plan that starts is not a plan that finishes unchanged.
Liver function can move, and with it the levels the label describes [1]. Medicines get added by other prescribers who do not know about the taper, and the CYP3A4 interactions are the ones to flag [1]. Pregnancy changes the calculation entirely, and the label is clear that prolonged use of opioids in pregnancy can lead to neonatal opioid withdrawal syndrome in the baby, which it describes as expected and treatable [1].
Alcohol and other sedatives matter too, and not only as an interaction. Where more than one substance is involved, the withdrawal that matters most may not be the opioid one.
Then there is everything that is not pharmacology. Housing, work, a court date, someone leaving. These are the reasons a plan gets paused, and pausing is a normal clinical decision rather than a failure. Our page on how long rehab takes covers the same point about treatment generally.
Where This Happens: Levels of Care
Not all of this needs a bed, and not all of it can be done in a fifteen-minute appointment.
Most buprenorphine treatment is outpatient, and most of this work happens that way too. Where it does not hold, or where other substances are in play, a more supervised setting is the answer rather than a stronger resolution. Our levels of care explainer describes the full ladder, from inpatient rehab down to outpatient care.
The Recovery Village Ridgefield publishes six levels on its own page: medical detox, inpatient treatment, partial hospitalization programming, intensive outpatient programming, dual diagnosis treatment and medically-assisted treatment [6]. That last one matters here, because a campus that runs medication treatment is a campus that can review a taper rather than only admit someone who has already stopped.
What Happens After the Medicine Stops
The plan should already say.
The label advises that patients be told about the potential to relapse to illicit drug use after discontinuation [1]. That is not a prediction about any one person. It is a reason to have the next appointment booked before the last reduction happens, rather than after something goes wrong.
Ask three questions while you are still in treatment. Who am I seeing, and when. What is the plan if the cravings come back. And what happens if I want to restart the medicine, which is a normal outcome rather than a defeat.
Naloxone in the house is worth raising in the same conversation, for the tolerance reason above [5]. Our page on withdrawal symptoms describes what stopping involves across drug classes.
Getting Help With Coming Off Suboxone
If you are on Suboxone and thinking about stopping, the next step is an appointment rather than a decision.
Bring three things to it. How long you have been on the medicine. What else you take, prescribed or not. And what is actually driving the wish to stop, because the answer changes the plan. Cost, side effects, a pharmacy problem and a job that tests for opioids all point at different solutions, and some of them do not involve stopping at all.
If you are not currently in treatment and are trying to come off without a prescriber, an assessment is the way in. Our page on how admission works sets out the order of events, and our guide to whether insurance covers rehab explains what a benefits check produces before the first call.
Frequently Asked Questions
How long does a Suboxone taper take? There is no standard answer. The FDA label says only to stop by tapering gradually, so that withdrawal signs and symptoms are avoided. It publishes no universal schedule, and this page will not invent one. MedlinePlus puts the same thing to patients: your doctor will tell you when and how to stop. How long it takes depends on your history and is reviewed as it goes.
Will I get withdrawal symptoms while tapering? You may, and that is what a gradual reduction is designed to limit. MedlinePlus says stopping buprenorphine, or buprenorphine and naloxone, too quickly can cause withdrawal symptoms, and lists hot or cold flushes, restlessness, teary eyes, runny nose, sweating, chills, muscle pain, vomiting and diarrhea. Symptoms appearing is information for the prescriber, not a reason to push on alone.
Can I taper off Suboxone at home? That is not a decision to make alone, whatever the setting turns out to be. MedlinePlus is explicit that you should not stop taking this medicine without talking to your doctor. Plenty of tapering happens in outpatient care rather than in a hospital bed, but the plan, the pace and the reviews belong to a prescriber who knows your history.
What medications are used? The FDA has approved three medicines for opioid use disorder: buprenorphine, methadone and naltrexone. Which one has a role, and when, is a clinical decision. Alongside them, guidance for withdrawal management describes symptomatic treatment for the things withdrawal causes, such as nausea, cramps, anxiety and sleeplessness. No amounts appear on this page by design.
What comes after a taper? Follow-up, and it should be arranged before the last reduction. The label advises that patients be told about the potential to relapse to illicit drug use after stopping. The safety point is tolerance: withdrawal reduces it, so a return to opioid use after coming off can cause an overdose at a much smaller amount than before. If someone is having a seizure, is unresponsive or has trouble breathing, call 911. For a mental health crisis, call or text 988. Naloxone in the house is worth raising with the prescriber for the same reason. Restarting the medicine is a normal outcome, not a failure.
Sources
- U.S. National Library of Medicine. (2026). Buprenorphine and Naloxone Sublingual Film — Full Prescribing Information: Discontinuing Treatment, Warnings and Precautions, Drug Abuse and Dependence, Clinical Pharmacology. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4210afeb-474c-d842-d68e-af7e0021851a
- U.S. National Library of Medicine. Buprenorphine Sublingual and Buccal (opioid dependence). MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a605002.html
- U.S. Food and Drug Administration. Information about Medications for Opioid Use Disorder (MOUD). https://www.fda.gov/drugs/food-and-drug-administration-overdose-prevention-framework/information-about-medications-opioid-use-disorder-moud
- World Health Organization. (2009). Clinical Guidelines for Withdrawal Management and Treatment of Drug Dependence in Closed Settings, Chapter 4: Withdrawal Management. National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/books/NBK310652/
- MedlinePlus Medical Encyclopedia. Opiate and opioid withdrawal. U.S. National Library of Medicine. https://medlineplus.gov/ency/article/000949.htm
- The Recovery Village. The Recovery Village Ridgefield — Levels of Care. Advanced Recovery Systems. https://www.therecoveryvillage.com/locations/ridgefield/
This page is for general information and is not medical advice. Only a licensed clinician who knows your history can tell you what is right for you. If you or someone you know is in immediate danger, call 911. For free, confidential support 24/7, call or text 988.
Author
Chief Medical Officer,
The Recovery Village
